Christopher Belletieri, DO
Family Medicine · Bristol, PANPI 1174562904
Payments from drug & device makers
Across 354 payments — averaging $32.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Abbott$890
- Amarin Pharma, Inc.$560
- AstraZeneca$512
- Amgen$495
- GSK$471
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,42512%
- Speaking & faculty fees$2,80025%
- Travel & lodging$6696%
- Food & beverage$6,44957%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $5,968 |
| Abbott | 30 | $890 |
| Amarin Pharma, Inc. | 45 | $560 |
| AstraZeneca | 36 | $512 |
| Amgen | 12 | $495 |
| GSK | 21 | $471 |
| Novo Nordisk | 23 | $404 |
| Pfizer | 23 | $350 |
| Kowa Pharmaceuticals America, Inc. | 16 | $212 |
| Exact Sciences | 9 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $169 |
| Otsuka America Pharmaceutical, Inc. | 9 | $161 |
| Lilly USA, LLC | 8 | $138 |
| Boehringer Ingelheim | 5 | $92 |
| Astellas Pharma US Inc | 4 | $73 |
| Bayer | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $64 |
| Novartis | 3 | $61 |
| Biohaven Pharmaceuticals, Inc. | 4 | $57 |
| Lundbeck LLC | 3 | $57 |
| Corcept Therapeutics | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Shire North American Group Inc | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Merck | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $21 |
| Althera Pharmaceuticals LLC | 1 | $17 |
| Medicomp Inc | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,402 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $59,519 |
| FarxigaDapagliflozin Propanediol | 72 | $53,320 |
| OzempicSemaglutide | 35 | $44,491 |
| XareltoRivaroxaban | 46 | $41,224 |
| MounjaroTirzepatide | 23 | $27,736 |
| JanuviaSitagliptin Phosphate | 33 | $23,795 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,619 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $20,787 |
| VascepaIcosapent Ethyl | 30 | $15,322 |
| LinzessLinaclotide | 27 | $14,670 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,243 |
| Spiriva RespimatTiotropium Bromide | 15 | $12,689 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,742 |
| Emgality PenGalcanezumab-Gnlm | 14 | $8,999 |
| MyrbetriqMirabegron | 18 | $7,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $512 | $71,752112 claims |
| PfizerEliquis | $350 | $59,51968 claims |
| MerckJanuvia, Janumet | $31 | $44,58249 claims |
| Novo NordiskOzempic | $404 | $44,49135 claims |
| Johnson & JohnsonXarelto | $21 | $41,22446 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $471 | $38,41057 claims |
| Lilly USA, LLCMounjaro | $138 | $27,73623 claims |
| AbbVieLinzess | $5,968 | $14,67027 claims |
| Boehringer IngelheimSpiriva Respimat | $92 | $12,68915 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $7,62418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Bristol
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.